Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Genomic Variant May Predict Cardiotoxicity From Chemotherapy
Clinical Breakthroughs

Genomic Variant May Predict Cardiotoxicity From Chemotherapy

By Melissa RohmanJan 3, 2022
Share
Facebook Twitter Email
Paul Burridge, PhD, assistant professor of Pharmacology and member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study published in Circulation.

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.

The findings underscore the significance of identifying reliable predictive genomic biomarkers and their potential to improve the course of treatment plans and overall patient outcomes, according to Paul Burridge, PhD, assistant professor of Pharmacology and senior author of the study.

“This is good news for patients because potentially we can predict which patients are more or least likely to experience cardiotoxicity and modify their treatment accordingly,” said Burridge, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Doxorubicin, an anthracycline chemotherapy drug, is mainly used as a last line of defense for patients diagnosed with cancer, most often pediatric cancers and breast cancers, who have no other chemotherapy treatment options.

While the drug has proven effective in slowing the growth of cancer cells, about 10 percent of patients will experience some form of cardiotoxicity from the drug, ranging from a reduction in ejection fraction — how well the heart’s left ventricle pumps blood — to heart failure, including requiring a heart transplant.

“Sadly, these patients with their previous history of cancer aren’t necessarily good candidates to be selected for a heart transplant,” Burridge said.

To pinpoint why doxorubicin causes cardiotoxicity in just a fraction of these patients, Burridge and his collaborators used previous work suggesting a variant in the gene SLC28A3 was statistically associated with doxorubicin cardiotoxicity to springboard their current study.

The SLC28A3 protein is also known as an uptake transporter that brings drugs into cancer cells and is only be expressed in cardiomyocytes, specialized cells that help the heart contract, according to Burridge.

Expression of SLC28A3 protein in human induced pluripotent stem cell-derived cardiomyocytes.

With this knowledge in hand, the investigators engineered cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) from six pediatric patients. Half of these patients had the SLC28A3 variant and all patients had been treated with doxorubicin.

Using hiPSC-derived cardiomyocytes, the investigators found that cells from patients who had the SLC28A3 variant experienced less cardiotoxicity from the chemotherapy drug.

Knocking out SLC28A3 in cell lines also demonstrated a reduction in cardiotoxicity. However, the investigators also found that the SLC28A3 variant was a synonymous mutation and did not change the protein, further suggesting that another genomic variant was in fact responsible.

The investigators then developed a simple gene sequencing methodology using Nanopore DNA sequencing and identified a novel genomic variant in SLC28A3 called s11140490 that was located by long noncoding-RNA, having direct impact on SLC28A3 gene expression.

By simply screening patients for this variant, Burridge said, clinicians could be able to predict which patients will be protected from doxorubicin-induced cardiotoxicity. The study also establishes a model for screening clinically approved drugs for how well they transport doxorubicin into cardiomyocytes, according to Burridge.

Using this model, Burridge’s team found that the drug desipramine, a tricyclic antidepressant, inhibited the transport of doxorubicin into cardiomyocytes.

By studying mouse models treated with desipramine and then doxorubicin, the investigators found that cardiotoxicity in the mice was reduced by almost half.

“Desipramine is an already FDA-approved drug, so that means the route towards this therapy being used clinically is much shorter,” Burridge said.

Burridge said his team is now collaborating with the Lurie Cancer Center to begin testing desipramine’s efficacy in clinical trials, as well as to confirm that there are no issues with reducing the efficacy of chemotherapy.

“Reducing cardiotoxicity that only occurs in 10 percent of people down to 5 percent is quite difficult to test and we need a lot of patients, but we’re quite excited about how that’s going to go moving forward,” Burridge said.

Co-authors include Carly Weddle and Marisol Romero Tejeda, students in the Driskill Graduate Program in Life Sciences (DGP).

This work was supported by National Institutes of Health grants K99/R00 HL121177, R01 CA220002, R01 CA261898, American Heart Association Transformational Project Award 18TPA34230105 and Fondation Leducq.

Cancer Patient Care Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Comments are closed.

Latest News

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.